Safety and Efficacy of RK0202 in Oral Mucositis

Sponsor

RxKinetix (Industry)

Overall Status

Completed

CT.gov ID

NCT00230191

Collaborator

(none)

110

Enrollment

Locations

Duration (Months)

12.2

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer. Concurrent chemotherapy is not allowed in the study.

Condition or Disease	Intervention/Treatment	Phase
Mouth Diseases Mouth Ulcers Oral Mucositis Head and Neck Cancer	Drug: RK-0202	Phase 2

Detailed Description

Approximately 42,000 new cases of head and neck squamous cell carcinoma occur annually in the United States. Radiotherapy ("RT") plays a significant role in the management of head and neck cancer. The most common and clinically significant toxicities arising from head and neck radiation therapy are acute mucositis and acute and chronic xerostomia (dry mouth or salivary gland changes). In subjects receiving RT for cancers of the oral cavity or oropharynx the incidence of acute mucositis can exceed 90%. The painful ulceration of the oral mucosa produced by the radiation often leads to the requirement for narcotics to control pain, inability to eat, dehydration, the need for parenteral nutrition and, sometimes, breaks in RT. In addition to its symptomatic cost, the presence of mucositis has been associated with a number of other adverse outcomes including higher costs and more frequent hospitalizations.

Study Design

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Prevention

Official Title:

Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region

Study Start Date :

Jan 1, 2003

Study Completion Date :

Dec 1, 2005

Outcome Measures

Primary Outcome Measures

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis. []

Secondary Outcome Measures

The secondary objectives of the study are to assess the safety and tolerability of RK-0202 in these subjects and to explore whether the ProGelz™ vehicle alone is active in these subjects. []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Males or females 18 years and older with confirmed tumors of the oral cavity, oropharynx, nasopharynx, salivary glands, or supraglottic region who are intended for treatment with RT alone (no concomitant chemotherapy).
In post-operative patients, RT must begin no later than 9 weeks following surgery.
Intended for treatment with an RT regimen that will deliver a minimum of 60 Gy over 5-8 weeks to at least 2cm2 of three or more of seventeen protocol-specific oral cavity anatomical sites. Each qualifying site must receive a minimum of 60 Gy and there must be at least three such sites. (See section 5.3.1). Regimens may consist of:
single dose daily fractionated (daily max 2.2 Gy)
hyperfractionated (daily max 2.4 Gy)
concurrent boost (daily max during boost 3.3 Gy)
The minimum planned duration of treatment must be 5 weeks and the maximum 8 weeks.
Ability to undergo oral assessments.
Ability to begin dosing with study drug on day 1 of RT.
Karnofsky Performance Score > 60.
Ability to understand the protocol and provide informed consent.
If female, have negative serum pregnancy test.

Exclusion Criteria:

Planned use of concomitant chemotherapy.
Planned use of amifostine.
Presence of oral mucositis.
Prior radiotherapy to the head and neck.
T1 or T2 glottic tumors.
Other investigational drugs in the 14 days preceding initiation of study medication or during administration of study medication.
Other investigational or mucoprotective therapy for the prevention of oral mucositis, including, but not limited to, -carotene, tocopherol, laser irradiation, brushing the oral mucosa with silver-nitrate prophylactically, systemic TGF-β (transforming growth factor beta), misoprostol, pentoxifylline, leucovorin, allopurinol mouthwashes, systemic KGF (keratinocyte growth factor) or pilocarpine. Oral rinses with hydrogen peroxide, sucralfate, or chlorhexidine gluconate are also not permitted during the study.
Serious recent non-malignant medical condition which, in the opinion of the investigator, makes the patient unsuitable for study participation.
Medical, sociological, or psychological impediment to probable compliance with protocol.
Inability to undergo repeat treatments, clinical evaluations and other diagnostic procedures required by the protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UCLA Medical Center	Los Angeles	California	United States	90095
2	H Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	United States	33612
3	Commonwealth ENT	Louisville	Kentucky	United States	40207
4	University of Connecticutt	Farmington	Massachusetts	United States	06030
5	Medical University of Ohio, Cancer Institute Ruppert Cancer Center	Toledo	Ohio	United States	43614
6	MD Anderson Cancer Center	Houston	Texas	United States	77030
7	Cross Cancer Institute	Edmonton	Alberta	Canada	T6G1Z2
8	Juravinski Cancer Center	Hamilton	Ontario	Canada	L8V5C2
9	University of Ottawa	Ottawa	Ontario	Canada	K1H1C4

Sponsors and Collaborators

RxKinetix

Investigators

Study Director: Steve Sonis, DMD DMSc, Harvard, Oral Medicine, Infection & Immunology
Principal Investigator: Doug Peterson, DMD, University of Connecticutt Health Center
Principal Investigator: Guy Juillard, MD, University of California, Los Angeles
Principal Investigator: Mark Chambers, DMD MS, MD Anderson
Principal Investigator: Andy Trotti, MD, H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator: John Feldmeier, DO, Medical University of Ohio
Principal Investigator: Samy El Sayed, MD, Ottawa Regional Cancer Centre
Principal Investigator: Rufus Scrimger, MD, Cross Cancer Institute, Edmonton, CA
Principal Investigator: Jim Wright, MD, Juravinski Cancer Centre Hamilton Health Sciences
Principal Investigator: Donald Welsh, MD, Commonwealth ENT, Louisville, KY